Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.43 |
| ▸ | TEK | Q02763 | 4/20 | 0.43 |
| ▸ | GRM5 | P41594 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581185 | 0.84 | LCK (0.43) | LCKTEKGRM5KDRFFAR1 | |
| SCHEMBL4717843 | 0.83 | GRM5 (0.43) | LCKTEKGRM5KDR | |
| SCHEMBL27672591 | 0.80 | LCK (0.42) | LCKTEKGRM5KDRFFAR1 | |
| SCHEMBL4618819 | 0.76 | LCK (0.56) | LCKTEKGRM5KDR | |
| SCHEMBL27672622 | 0.75 | VNN1 (0.42) | LCKTEKGRM5KDRFFAR1 | |
| SCHEMBL4717456 | 0.75 | PDGFRB (0.43) | LCKTEKGRM5KDR | |
| SCHEMBL27672607 | 0.74 | GRM5 (0.45) | LCKTEKGRM5KDRPTGDR2 | |
| SCHEMBL27672587 | 0.74 | GRM5 (0.47) | LCKTEKGRM5KDR | |
| SCHEMBL5101060 | 0.74 | EGLN1 (0.42) | LCKTEKGRM5FFAR1EGLN1 | |
| SCHEMBL3568737 | 0.74 | GRM5 (0.37) | LCKTEKGRM5KDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | LCK 391/4885TEK 2/4885GRM5 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.